Evolus Reports 6.7% Revenue Growth to $73.1 Million in Q1 2026

Evolus, Inc. reported its financial results for the first quarter of 2026, revealing a net revenue of $73.1 million, a 6.7% increase from $68.5 million in the same period last year. The growth was primarily driven by the launch of its Evolysse® product line in the United States and the continued international expansion of its flagship product, Jeuveau®. The company recorded a gross profit of $48.9 million, resulting in a gross profit margin of 66.9%, slightly down from 68.1% in the prior year. Despite the revenue increase, Evolus reported a net loss of $10.7 million, an improvement from the $18.9 million loss recorded in the first quarter of 2025.

In terms of operational efficiency, Evolus has made significant strides, reducing its total operating expenses to $55.7 million from $61.8 million year-over-year. This reduction was largely attributed to strategic cost optimization initiatives, particularly in selling, general, and administrative expenses, which fell by 8.2% to $52.0 million. The company’s research and development expenses remained stable at $2.2 million, indicating a consistent investment in future product development.

Evolus has also made notable advancements in its product offerings. The company launched Evolysse® Form and Evolysse® Smooth in April 2025, with plans to introduce additional products, Evolysse® Sculpt and Evolysse® Lips, in the U.S. in 2026 and 2027, respectively. The company anticipates launching all four Evolysse® products in Europe in the second quarter of 2026. As of March 31, 2026, Evolus had cash and cash equivalents of $49.8 million, with an accumulated deficit of $671.7 million, reflecting ongoing investments in product development and commercialization.

Evolus is also navigating a complex regulatory and economic landscape, with potential impacts from tariffs and geopolitical tensions affecting consumer sentiment and discretionary spending. The company has entered into a Loan and Security Agreement with Eclipse Business Capital LLC, securing a $30 million revolving credit facility to bolster its liquidity. This facility, along with existing financing arrangements, is expected to support Evolus's operations and growth initiatives over the next twelve months.

Looking ahead, Evolus remains focused on expanding its customer base and increasing product adoption in the competitive aesthetic market. The company is optimistic about the future, contingent on successful product launches and regulatory approvals, while also being mindful of the economic factors that could influence its performance.